SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Multiple Sclerosis
This Article
Right arrow Full Text (OnlineFirst PDF)
Right arrow All Versions of this Article:
1352458507076970v1
13/7/884    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Soon, D
Right arrow Articles by Miller, D H
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Soon, D
Right arrow Articles by Miller, D H
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Article

Quantification of subtle blood-brain barrier disruption in non-enhancing lesions in multiple sclerosis: a study of disease and lesion subtypes

D Soon, D J Tozer, D R Altmann, P S Tofts, D H Miller*

NMR Research Unit, Department of Neuroinflammation, Institute of Neurology, University College London, London, UK

* To whom correspondence should be addressed.


  Abstract

Few attempts have been made to detect subtle blood-brain barrier (BBB) leakage in visibly non-enhancing MRI lesions in multiple sclerosis (MS). For 19 patients, longitudinal relaxation time (T1) maps were generated from MRI scans obtained before, and at 20, 40 and 60 minutes after injection of gadolinium (Gd)-DTPA (0.3 mmol/kg). Regions of interest (ROI) were placed around non-enhancing lesions, and in paired contralateral normal appearing brain tissue (NABT). Post-Gd rate of R1 (51/T1) rise ({Delta}R1/{Delta}t), was used to quantify leakage. {Delta}R1/{Delta}t was greater in lesions than paired NABT (P≤0.001 at all post-Gd timepoints). {Delta}R1/{Delta}t was greater in T1 hypointense than isointense lesions (P50.001 and 0.01 for first and second timepoints respectively), and negatively related to lesion cross sectional area (P≤0.001 at all post-Gd timepoints). Relapsing remitting (RRMS) lesions had a greater initial {Delta}R1/{Delta}t than secondary progressive (SPMS) lesions (P50.04), but this was not seen in subsequent timepoints. {Delta}R1/{Delta}t in visibly enhancing lesions was significantly greater than in visibly non-enhancing lesions, with no overlap in the normal ranges of the two populations. Subtle BBB leakage is a consistent feature in non-enhancing lesions, and is distinct from the overt BBB leakage observed in visibly enhancing lesions. It is detectable using quantitative contrast-enhanced MRI. It is apparent in all clinical and lesion subtypes studied, and greater in T1 hypointense and smaller lesions. Larger initial {Delta}R1/{Delta}t in RRMS than SPMS lesions may reflect differences in blood volume rather than BBB leakage. Multiple Sclerosis 2007; 00: 000-000. http://msj.sagepub.com

Key Words: blood brain barrier; multiple sclerosis; non-enhancing lesions; T1 maps

First published on April 27, 2007, doi:10.1177/1352458507076970

Multiple Sclerosis 2007;13:884.

A more recent version of this article appeared on August 1, 2007

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




Advertisement